Overview

Daratumumab to Treat Active Lupus Nephritis

Status:
Recruiting

Trial end date:
2023-09-04

Target enrollment:

Participant gender:

Summary

The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.

Phase:

Phase 2

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Daratumumab